Literature DB >> 25983440

Bilateral symmetrical digital gangrene of upper and lower limbs due to purpura fulminans caused by Streptococcus pyogenes: A rare entity.

Goyal Kush Ashokkumar1, Rao Madhu1, Mathew Shaji1, Budania Raghuveer Singh2.   

Abstract

Entities:  

Year:  2015        PMID: 25983440      PMCID: PMC4430752          DOI: 10.4103/0972-5229.156493

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


× No keyword cloud information.
Sir, We report an unusual case of 72-year-old female with acute gastroenteritis due to Streptococcus pyogenes, leading to low cardiac output state and acute kidney injury, who developed bilateral symmetrical peripheral gangrene (SPG) of upper and lower limbs [Figures 1 and 2]. All peripheral pulses were palpable and color Doppler of upper and lower limb vessels indicated normal flow. Investigations revealed hemoglobin 10.9 g/dL, platelet count 44,000 cells/mm3, PT INR 1.72, low antithrombin-lll levels and deranged liver function. Plasma was positive for fibrin degradation products and D-dimers. She was shifted to Intensive Care Unit suspecting septic shock and resuscitated with intravenous (IV) fluids and dopamine infusion. In view of persisting hypotension and desaturation, she was intubated and mechanically ventilated. Unfractionated heparin was started to treat digital gangrene, attributing it to the pro-thrombotic state of sepsis. She developed bleeding per vaginally and orally in course of 2 days while her PT-INR rose to 2.8, platelet count decreased to 11,000 cells/mm3 and fibrinogen levels were 65 mg/dL, indicative of consumptive coagulopathy. This was treated with transfusion of six units FFP, four units each of cryoprecipitate and platelet, and bleeding was controlled within 2 days.
Figure 1

Digital gangrene of both lower limbs, involving forefoot on the right side

Figure 2

Digital gangrene of both upper limbs

Digital gangrene of both lower limbs, involving forefoot on the right side Digital gangrene of both upper limbs After 72 h, blood culture was positive for S. pyogenes, sensitive to ceftriaxone, amoxicillin/ampicillin and tetracycline/doxycycline, which was started immediately. The diagnosis of pupura fulminans (PF) due to S. pyogenes leading to SPG was made. Her general condition improved within 72 h with no further progression of gangrenous areas, which were well delineated in a week. She was discharged against medical advice on day 11 due to the economic constraint. Pupura fulminans is an acute life-threatening complication of disseminated intravascular coagulation (DIC) manifested by rapidly progressive cutaneous hemorrhage and necrosis leading to SPG.[1] Clinical features include tissue necrosis, intact peripheral pulse, elevated serum lactate, association with vasospastic disorders and multi-organ failure. This is attributed to the pro-thrombotic state of DIC, which leads to widespread microvascular thrombosis.[2] Common pathogens responsible for PF include Meningococci, Pneumococci, Staphylococci, Klebsiella and Enterococci.[3] S. pyogenes the causative organism in our case has not been reported till now in the literature. Awareness of this clinical condition will help in the prompt recognition, early administration of treatment to prevent the spread of gangrenous areas and avoidance of expensive investigations like angiography or unwanted surgical procedure in the critically ill patient. Aggressive resuscitation using IV fluids, vasopressor infusions, correction of acid-base and electrolyte imbalance and mechanical ventilation can stop the spread of gangrenous area along with rapid recovery. Mortality associated with SPG can be reduced by early recognition and administration of culture sensitive antibiotics. Although heparinization is associated with thrombotic (peripheral gangrene) as well as bleeding tendencies (consumptive coagulopathy), posing therapeutic dilemma, it remains the mainstay of treatment to control thrombosis.[4] Amputation of gangrenous areas is deferred till the general condition of the patient improves, and the gangrenous area is well-demarcated.[3] Protection of gangrenous extremities with antiseptic dressing, halting the spread and demarcation by topical nitroglycerine paste, phentolamine, epoprostenol or sympathetic blockade can be tried.[2] Novel modalities of treatment include plasmapheresis, papaverine, streptokinase, hyperbaric oxygen therapy, dextran-40, epsilon aminocaproic acid, ketanserin, and hirudin.[13567]
  7 in total

1.  Symmetrical peripheral gangrene: a rare but dreadful complication of sepsis.

Authors:  Malvinder S Parmar
Journal:  CMAJ       Date:  2002-10-29       Impact factor: 8.262

Review 2.  Infectious purpura fulminans: diagnosis and treatment.

Authors:  O P Smith; B White
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

3.  Successful use of leeches in the treatment of purpura fulminans.

Authors:  T de Chalain; S R Cohen; F D Burstein
Journal:  Ann Plast Surg       Date:  1995-09       Impact factor: 1.539

4.  Symmetrical peripheral gangrene and disseminated intravascular coagulation.

Authors:  M A Molos; J C Hall
Journal:  Arch Dermatol       Date:  1985-08

5.  Review of management of purpura fulminans and two case reports.

Authors:  J Nolan; R Sinclair
Journal:  Br J Anaesth       Date:  2001-04       Impact factor: 9.166

6.  Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis.

Authors:  K Johansen; S T Hansen
Journal:  Am J Surg       Date:  1993-05       Impact factor: 2.565

Review 7.  Symmetrical peripheral gangrene.

Authors:  B D Sharma; S R Kabra; B Gupta
Journal:  Trop Doct       Date:  2004-01       Impact factor: 0.731

  7 in total
  1 in total

Review 1.  Streptococcus pyogenes-purpura fulminans as an invasive form of group A streptococcal infection.

Authors:  Sayaka Okuzono; Masataka Ishimura; Shunsuke Kanno; Motoshi Sonoda; Noriyuki Kaku; Yoshitomo Motomura; Hisanori Nishio; Utako Oba; Masuo Hanada; Jun-Ichi Fukushi; Michiyo Urata; Dongchon Kang; Hidetoshi Takada; Shouichi Ohga
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-07-09       Impact factor: 3.944

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.